José Baselga
AstraZeneca says that treme flubbed another combo cancer study, raising fresh doubts about a serial loser
AstraZeneca’s badly damaged CTLA-4 strategy on the immuno-oncology front has taken another hit.
The pharma giant put out word that the second leg of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
